Half-effective target effect-site concentration of sufentanil required to inhibit body movement during insertion of ureteroscopes when combined with propofol
10.3760/cma.j.issn.0254-1416.2010.10.023
- VernacularTitle:复合异丙酚时舒芬太尼抑制置入输尿管镜时病人体动反应的半数有效效应室靶浓度
- Author:
Shaoyan LIU
;
Yingzhi LIU
;
Shiduan WANG
;
Yongbo LIU
;
Chunqin CHU
;
Jingxia LIANG
- Publication Type:Journal Article
- Keywords:
Sufentanil;
Propofol;
Drug delivery systems;
Dose-response relationship,drug;
Ureteroscopes
- From:
Chinese Journal of Anesthesiology
2010;30(10):1230-1232
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine the half-effective target effect-site concentration (Ce) (EC50) of sufentanil required to inhibit the body movement during insertion of ureteroscopes when combined with propofol in patients undergoing transureteroscopic holmium laser lithotripsy. Methods Fifty ASA Ⅰ or Ⅱ patients of both sexes, aged 20-60 yr, BMI ＜ 30 kg/m2 , undergoing transureteroscopic holmium laser lithotripsy were randomly divided into 5 groups according to the different C es of sufentanil ( n = 10 each): group S1 (Ce 0.21 ng/ml), group S2(Ce 0.14 ng/ml), group S3(Ce 0.09 ng/ml), group S4(Ce 0.06 ng/ml), group S5(Ce 0.04 ng/ml). TCI of propofol with target plasma concentration set at 2.5-3.0 μg/ml was given. Sufentanil with the corresponding Ce was infused in each group. The ureteroscopes were inserted as soon as the patients lost consciousness and the effect-site concentration of sunfentanil was achieved. The response was defined as positive when body movement occurred within 1 min after insertion of ureteroscopes. The EC50 of sufentanil required to inhibit the body movement during insertion of ureteroscopes when combined with propofol and 95% confidence interval (CI) were calculated. Results The EC50 of sufentanil required to inhibit the body movement during insertion of ureteroscopes when combined with propofol was 0.084 ng/ml and 95% CI was 0.066-0.107 ng/ml. Conclusion The EC50 of sufentanil required to inhibit the body movement during insertion of ureteroscopes was 0.084 ng/ml when combined with propofol.
